

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
18 October 2018 (18.10.2018)



(10) International Publication Number
WO 2018/190990 A1

(51) International Patent Classification:
C12Q 1/6883 (2018.01)

(21) International Application Number:
PCT/US2018/023266

(22) International Filing Date:
20 March 2018 (20.03.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/485,077 13 April 2017 (13.04.2017) US

(71) Applicant: REGENERON PHARMACEUTICALS,
INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown,
New York 10591 (US).

(72) Inventors: BRUSE, Shannon; 777 Old Saw Mill River
Road, Tarrytown, New York 10591 (US). MCCARTHY,
Shane; 777 Old Saw Mill River Road, Tarrytown, New
York 10591 (US). BARAS, Aris; 777 Old Saw Mill River
Road, Tarrytown, New York 10591 (US). DEWEY, Fred-
erick; 777 Old Saw Mill River Road, Tarrytown, New York
10591 (US). GOTTESMAN, Omri; 777 Old Saw Mill Riv-
er Road, Tarrytown, New York 10591 (US).

(74) Agent: LEGAARD, Paul K.; Stradley Ronon Stevens &
Young, LLP, 30 Valley Stream Parkway, Malvern, Penn-
sylvania 19355-1481 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS HAVING RISK ALLELES IN THE GENES ENCODING IL33 AND IL1RL1

(57) Abstract: IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof.



WO 2018/190990 A1